首页 | 本学科首页   官方微博 | 高级检索  
检索        

食蟹猴静脉注射抗HER2人源化抗体急性毒性研究
引用本文:周晓冰,孙立,盛晓丽,吕建军,苗玉发,杨艳伟,霍艳,王雪,汪巨峰,李波.食蟹猴静脉注射抗HER2人源化抗体急性毒性研究[J].现代药物与临床,2015,38(6):637-639.
作者姓名:周晓冰  孙立  盛晓丽  吕建军  苗玉发  杨艳伟  霍艳  王雪  汪巨峰  李波
作者单位:中国食品药品检定研究院国家药物安全评价监测中心, 药物非临床安全评价研究北京市重点实验室, 北京 100176;中国食品药品检定研究院国家药物安全评价监测中心, 药物非临床安全评价研究北京市重点实验室, 北京 100176;北京天广实生物技术股份有限公司, 北京 101111;中国食品药品检定研究院国家药物安全评价监测中心, 药物非临床安全评价研究北京市重点实验室, 北京 100176;中国食品药品检定研究院国家药物安全评价监测中心, 药物非临床安全评价研究北京市重点实验室, 北京 100176;中国食品药品检定研究院国家药物安全评价监测中心, 药物非临床安全评价研究北京市重点实验室, 北京 100176;中国食品药品检定研究院国家药物安全评价监测中心, 药物非临床安全评价研究北京市重点实验室, 北京 100176;中国食品药品检定研究院国家药物安全评价监测中心, 药物非临床安全评价研究北京市重点实验室, 北京 100176;中国食品药品检定研究院国家药物安全评价监测中心, 药物非临床安全评价研究北京市重点实验室, 北京 100176;中国食品药品检定研究院国家药物安全评价监测中心, 药物非临床安全评价研究北京市重点实验室, 北京 100176
基金项目:十二五“重大新药创制”科技重大专项(2012ZX09302001)
摘    要:目的 评价抗HER2 人源化抗体的急性毒性。方法 将食蟹猴随机分为4 组,包括溶媒对照和抗HER2 人源化抗体75、150 和250 mg/kg 组,单次iv 溶媒对照组或供试品,进行各项毒理学指标检测。结果 给药后各组动物临床症状、体质量、摄食量、体温、心电图、血压和血液学检测均未见明显异常;血清生化结果显示,150 mg/kg 组与250 mg/kg 组动物给药后血清IgG 水平出现一过性增加;各组动物均未见大体病理学改变。结论 食蟹猴单次iv 抗HER2 单抗,总体上动物具有良好的耐受性,最大耐受剂量可达250 mg/kg,这些结果为进一步临床前评价抗HER2 人源化单克隆抗体的安全性奠定了基础。

关 键 词:抗HER2  人源化抗体  急性毒性  安全性  临床前研究
收稿时间:2015/9/17 0:00:00

Acute toxicity of humanized anti-HER2 monoclonal antibody on cynomolgus monkeys after intravenous administration
ZHOU Xiao-bing,SUN Li,Sheng Xiao-Li,LU Jian-jun,MIAO Yu-f,YANG Yan-wei,HUO Yan,WANG Xue,WANG Ju-feng and LI Bo.Acute toxicity of humanized anti-HER2 monoclonal antibody on cynomolgus monkeys after intravenous administration[J].Drugs & Clinic,2015,38(6):637-639.
Authors:ZHOU Xiao-bing  SUN Li  Sheng Xiao-Li  LU Jian-jun  MIAO Yu-f  YANG Yan-wei  HUO Yan  WANG Xue  WANG Ju-feng and LI Bo
Institution:National Center for Safety Evaluation of Drugs, National Institutes for Food and Drug Control, Beijing 100176, China;National Center for Safety Evaluation of Drugs, National Institutes for Food and Drug Control, Beijing 100176, China;Mabworks Biotech Co. Ltd. Beijing 101111, China;National Center for Safety Evaluation of Drugs, National Institutes for Food and Drug Control, Beijing 100176, China;National Center for Safety Evaluation of Drugs, National Institutes for Food and Drug Control, Beijing 100176, China;National Center for Safety Evaluation of Drugs, National Institutes for Food and Drug Control, Beijing 100176, China;National Center for Safety Evaluation of Drugs, National Institutes for Food and Drug Control, Beijing 100176, China;National Center for Safety Evaluation of Drugs, National Institutes for Food and Drug Control, Beijing 100176, China;National Center for Safety Evaluation of Drugs, National Institutes for Food and Drug Control, Beijing 100176, China;National Center for Safety Evaluation of Drugs, National Institutes for Food and Drug Control, Beijing 100176, China
Abstract:Objective To evaluate the single dose toxicity of a humanized anti-HER2 monoclonal antibody. Methods Cynomolgus monkeys were randomly divided into four groups: vehicle control, 75, 150, and 250 mg/kg. All animals were iv administered with a single-dose vehicle control or test article. Then a series of toxicological parameters were determined. Results Following a single iv injection with anti-HER2 monoclonal antibody, there were not obvious abnormalities in clinical symptom, food consumption, weight, temperature, electrocardiogram, blood pressure, and hematology analysis for all article-treated groups. A transient increase of serum IgG was observed in 150 and 250 mg/kg dosage groups. No macro-pathological change was found in all animals. Conclusion Single iv injection with anti-HER2 monoclonal antibody was well tolerated in cynomolgus monkeys. The maximum tolerated dose of anti-HER2 monoclonal antibody is greater than that of 250 mg/kg. These results will facilitate further preclinical safety studies of humanized anti-HER2 monoclonal antibody.
Keywords:humanized anti-HER2 monoclonal antibody  acute toxicity  safety  preclinical study
点击此处可从《现代药物与临床》浏览原始摘要信息
点击此处可从《现代药物与临床》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号